Taysha completes REVEAL pivotal trial dosing; longer-term data shows durable functional gains in Rett syndrome

Taysha Gene Therapies, Inc.

Completed dosing of 17 patients in REVEAL pivotal trial; topline 6-month interim data and FDA feedback expected 1H 2027.
100% of 12 REVEAL Part A patients gained/regained ≥1 developmental milestone by 12 months post-TSHA-102.
No treatment-related SAEs or DLTs across 29 patients dosed as of June 2026 cutoff.
310 total functional gains observed ≥12 months post-treatment (~26 per patient) across core disease domains.
ASPIRE trial enrollment exceeded; expects to dose 4th patient in July 2026; safety data to support BLA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.